AVBP Valuation

Arrivent Biopharma Inc

Add to Watchlist

Advanced Chart

19.120

-0.09(-0.469%)1D

Overview
Forecast
Valuation
Earnings

AVBP Relative Valuation

AVBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AVBP is overvalued; if below, it's undervalued.

Historical Valuation

Arrivent Biopharma Inc (AVBP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.14. The fair price of Arrivent Biopharma Inc (AVBP) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：19.21

Fair

-5.45

Trailing

Forward

-3.47

EV/EBITDA

Arrivent Biopharma Inc. (AVBP) has a current EV/EBITDA of -3.47. The 5-year average EV/EBITDA is -5.09. The thresholds are as follows: Strongly Undervalued below -7.98, Undervalued between -7.98 and -6.54, Fairly Valued between -3.65 and -6.54, Overvalued between -3.65 and -2.21, and Strongly Overvalued above -2.21. The current Forward EV/EBITDA of -3.47 falls within the Overvalued range.

-3.56

EV/EBIT

Arrivent Biopharma Inc. (AVBP) has a current EV/EBIT of -3.56. The 5-year average EV/EBIT is -4.81. The thresholds are as follows: Strongly Undervalued below -7.73, Undervalued between -7.73 and -6.27, Fairly Valued between -3.35 and -6.27, Overvalued between -3.35 and -1.89, and Strongly Overvalued above -1.89. The current Forward EV/EBIT of -3.56 falls within the Historic Trend Line -Fairly Valued range.

0.00

Arrivent Biopharma Inc. (AVBP) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-6.39

P/OCF

Arrivent Biopharma Inc. (AVBP) has a current P/OCF of -6.39. The 5-year average P/OCF is -5.93. The thresholds are as follows: Strongly Undervalued below -12.21, Undervalued between -12.21 and -9.07, Fairly Valued between -2.79 and -9.07, Overvalued between -2.79 and 0.36, and Strongly Overvalued above 0.36. The current Forward P/OCF of -6.39 falls within the Historic Trend Line -Fairly Valued range.

-5.58

P/FCF

Arrivent Biopharma Inc. (AVBP) has a current P/FCF of -5.58. The 5-year average P/FCF is -8.14. The thresholds are as follows: Strongly Undervalued below -12.24, Undervalued between -12.24 and -10.19, Fairly Valued between -6.10 and -10.19, Overvalued between -6.10 and -4.05, and Strongly Overvalued above -4.05. The current Forward P/FCF of -5.58 falls within the Overvalued range.

Arrivent Biopharma Inc (AVBP) has a current Price-to-Book (P/B) ratio of 2.88. Compared to its 3-year average P/B ratio of 2.47 , the current P/B ratio is approximately 16.54% higher. Relative to its 5-year average P/B ratio of 2.47, the current P/B ratio is about 16.54% higher. Arrivent Biopharma Inc (AVBP) has a Forward Free Cash Flow (FCF) yield of approximately -16.25%. Compared to its 3-year average FCF yield of -10.37%, the current FCF yield is approximately 56.69% lower. Relative to its 5-year average FCF yield of -10.37% , the current FCF yield is about 56.69% lower.

2.87

P/B

Median3y

2.47

Median5y

2.47

-16.25

FCF Yield

Median3y

-10.37

Median5y

-10.37

Competitors Valuation Multiple

The average P/S ratio for AVBP's competitors is 14.30, providing a benchmark for relative valuation. Arrivent Biopharma Inc Corp (AVBP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AVBP.O

Arrivent Biopharma Inc

EyePoint Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc

Phathom Pharmaceuticals Inc

3.75

439.36%

864.09M

Performance Decomposition

Market capitalization of AVBP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of AVBP in the past 1 year is driven by Unknown.